Mesa Laboratories, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023
February 05, 2024 at 08:02 am EST
Share
Mesa Laboratories, Inc. reported earnings results for the third quarter and nine months ended December 31, 2023. For the third quarter, the company reported sales was USD 53.47 million compared to USD 54.29 million a year ago. Net income was USD 2.12 million compared to USD 0.451 million a year ago. Basic earnings per share from continuing operations was USD 0.39 compared to USD 0.08 a year ago. Diluted earnings per share from continuing operations was USD 0.39 compared to USD 0.08 a year ago.
For the nine months, sales was USD 157.28 million compared to USD 163.49 million a year ago. Net income was USD 0.337 million compared to USD 0.319 million a year ago. Basic earnings per share from continuing operations was USD 0.06 compared to USD 0.06 a year ago. Diluted earnings per share from continuing operations was USD 0.06 compared to USD 0.06 a year ago.
Mesa Laboratories, Inc. is a multinational manufacturer, developer, and seller of life sciences tools and critical quality control solutions. Its segments include Clinical Genomics, Sterilization and Disinfection Control, Biopharmaceutical Development, and Calibration Solutions. Its Clinical Genomics segment develops, manufactures, and sells throughput genetic analysis tools used by labs to perform clinical genomic testing in several therapeutic areas. Its Sterilization and Disinfection Control segment manufactures and sells biological, chemical, and cleaning indicators used to assess the effectiveness of sterilization and disinfection processes. Biopharmaceutical Development segment develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. Its Calibration Solutions segment develops, manufactures, and sells quality control products used to measure or calibrate temperature, pressure, pH, humidity, and other such parameters.
MESA LABORATORIES, INC. 
